We anticipate continuing our improvement towards making ponatinib available to individuals with Ph+ and CML ALL,’ mentioned Harvey J. Berger, M.D., chairman and ceo of ARIAD. ‘If accepted, we believe that ponatinib can be an important new medication for CML and Ph+ ALL patients who’ve become intolerant or resistant to prior tyrosine kinase inhibitor therapy.’ ARIAD anticipates acceptance and commercial launch of ponatinib in the U.S. In the first one fourth of 2013. Also, the Marketing Authorization Software for ponatinib, august submitted in, has been validated by the European Medications Agency , commencing their overview of the software.Dr. Valina-Toth said certain medicines called cardioprotective drugs will help prevent this merit and damage investigation. Given the chance of chemotherapy-induced cardiotoxicity with both antracycline and trastuzumab, pretreatment with cardioprotective brokers such as ACE inhibitors or angiotensin II receptor blockers and beta blockers, in addition to monitoring cardiac function, have to be considered to initiation of chemotherapy prior, Dr. Valina-Toth stated. Related StoriesViralytics enters into scientific trial collaboration agreement with MSDMD Anderson research reveals why chemotherapy medications not effective for most pancreatic malignancy patientsCornell biomedical engineers develop 'super organic killer cells' to destroy cancer cells in lymph nodes Researchers identified 26,347 women with breast malignancy between 1973 and 2007 using the U.S.